Biomarx was founded by Sean Macfarlane, a passionate molecular and cellular biologist passionate about transforming biotechnology into real-world medical solutions. Originally aspiring to be a doctor, Sean realised that systemic barriers in healthcare often limit innovation. Instead, he pursued molecular and cellular biology at the University of Glasgow, focusing on disease pathology, genetics, and advanced biotechnologies.
Through both his academic and industry experience, Sean identified a critical gap between academic research and readily available clinical tools. Many groundbreaking medical discoveries never make it into clinical practice. Determined to change this, he founded Biomarx to develop cost-effective, accessible diagnostic technologies that enable early disease detection and improved patient outcomes.
Biomarx is committed to fostering collaboration, combining the innovation and expertise of academia-led research with the commercialisation capabilities of industry. By bridging the gap between academia and industry, Biomarx seeks to drive meaningful change in clinical practice, improving access to care and enhancing disease management for patients worldwide.
Biomarx is based in Belfast, Northern Ireland, and aims to collaborate with the University of Strathclyde on its first development project—a point-of-care device designed to replace targeted genome sequencing as a diagnostic tool, subject to a successful round of seed investment fundraising.